AU2003294930B2 - Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same - Google Patents

Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same Download PDF

Info

Publication number
AU2003294930B2
AU2003294930B2 AU2003294930A AU2003294930A AU2003294930B2 AU 2003294930 B2 AU2003294930 B2 AU 2003294930B2 AU 2003294930 A AU2003294930 A AU 2003294930A AU 2003294930 A AU2003294930 A AU 2003294930A AU 2003294930 B2 AU2003294930 B2 AU 2003294930B2
Authority
AU
Australia
Prior art keywords
antibody
cells
pharmaceutical composition
seq
ncr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003294930A
Other languages
English (en)
Other versions
AU2003294930A1 (en
Inventor
Pascale Andre
Francois Romagne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innate Pharma SA
Original Assignee
Innate Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma SA filed Critical Innate Pharma SA
Publication of AU2003294930A1 publication Critical patent/AU2003294930A1/en
Application granted granted Critical
Publication of AU2003294930B2 publication Critical patent/AU2003294930B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003294930A 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same Ceased AU2003294930B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43534402P 2002-12-23 2002-12-23
US60/435,344 2002-12-23
PCT/EP2003/014716 WO2004056392A1 (en) 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of nk cells and a method using the same

Publications (2)

Publication Number Publication Date
AU2003294930A1 AU2003294930A1 (en) 2004-07-14
AU2003294930B2 true AU2003294930B2 (en) 2008-12-04

Family

ID=32682222

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294930A Ceased AU2003294930B2 (en) 2002-12-23 2003-12-22 Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same

Country Status (6)

Country Link
US (1) US20080063717A1 (https=)
EP (1) EP1575615A1 (https=)
JP (1) JP2006514024A (https=)
AU (1) AU2003294930B2 (https=)
CA (1) CA2510787A1 (https=)
WO (1) WO2004056392A1 (https=)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
HRP20170342T1 (hr) * 2003-07-24 2017-05-19 Innate Pharma S.A. Metode i sastavi za povećanje učinkovitosti terapijskih protutijela koristeći tvari koje potenciraju nk stanice
US20070178106A1 (en) * 2004-04-30 2007-08-02 Innate Pharma, S.A. Compositions and methods for enhancing nk cell activity
US20090196850A1 (en) * 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
WO2007111714A2 (en) 2005-11-28 2007-10-04 Zymogenetics, Inc. Il-21 antagonists
US7883700B2 (en) 2007-12-07 2011-02-08 Zymogenetics, Inc. Anti-human IL-21 monoclonal antibodies
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
ES2765874T3 (es) 2011-05-25 2020-06-11 Innate Pharma Sa Anticuerpos anti-KIR para el tratamiento de trastornos inflamatorios
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
JP5997296B2 (ja) 2013-01-15 2016-09-28 阿部　博幸 免疫細胞含有組成物の製造方法及び癌治療用組成物
EP2824112B1 (en) 2013-07-10 2016-12-21 Miltenyi Biotec GmbH Method for inducing proliferation of Natural Killer cells by mobile nanomatrices
CN105462923B (zh) * 2014-12-17 2018-11-02 山东大学第二医院 一种人自然杀伤细胞体外高效扩增方法
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
US10786547B2 (en) 2015-07-16 2020-09-29 Biokine Therapeutics Ltd. Compositions, articles of manufacture and methods for treating cancer
US10736963B2 (en) 2015-07-24 2020-08-11 Innate Pharma Methods for detecting tissue infiltrating NK cells
EP3397645B1 (en) * 2015-12-28 2026-03-25 Innate Pharma Variable regions for nkp46 binding proteins
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3500298A4 (en) * 2016-08-17 2020-04-01 University Health Network REGULATION OF TUMOR ASSOCIATED T CELLS
MY206158A (en) 2017-05-24 2024-12-02 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
US12247060B2 (en) 2018-01-09 2025-03-11 Marengo Therapeutics, Inc. Calreticulin binding constructs and engineered T cells for the treatment of diseases
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CA3105448A1 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
CN111304248B (zh) 2018-12-25 2021-08-24 百奥赛图江苏基因生物技术有限公司 人源化细胞因子il15基因改造非人动物的构建方法及应用
JP7737306B2 (ja) 2019-02-21 2025-09-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞に結合する多機能性分子および自己免疫障害を処置するためのその使用
GB2599228B (en) 2019-02-21 2024-02-07 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EP3927746A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN119039441A (zh) * 2019-02-21 2024-11-29 马伦戈治疗公司 与nkp30结合的抗体分子及其用途
EP4084821A4 (en) 2020-01-03 2024-04-24 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3164182A1 (en) * 2020-01-17 2021-07-22 Liu XUE Anti-nkp30 antibodies and methods of use
CN115843312A (zh) 2020-04-24 2023-03-24 马伦戈治疗公司 结合至t细胞相关癌细胞的多功能性分子及其用途
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
GB2616128A (en) 2020-08-26 2023-08-30 Marengo Therapeutics Inc Antibody molecules that bind to NKp30 and uses thereof
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
KR102581230B1 (ko) * 2020-10-16 2023-09-21 의료법인 성광의료재단 항암 관련 유전자 발현이 조절된 자연살해세포 및 이의 용도
KR102236011B1 (ko) * 2020-11-11 2021-04-05 한바이오 주식회사 Nk 세포의 대량증식 배양방법
US12345068B2 (en) 2021-11-19 2025-07-01 Sundance Spas, Inc. Self-maintaining hot tub or spa
US12473529B2 (en) 2023-07-18 2025-11-18 Nanotein Technologies, Inc. Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979546B2 (en) * 1999-11-15 2005-12-27 Universita Di Genova Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells and antibodies that identify the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036630A2 (en) * 1999-11-15 2001-05-25 Innate Pharma S.A.S. Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same

Also Published As

Publication number Publication date
US20080063717A1 (en) 2008-03-13
AU2003294930A1 (en) 2004-07-14
JP2006514024A (ja) 2006-04-27
CA2510787A1 (en) 2004-07-08
EP1575615A1 (en) 2005-09-21
WO2004056392A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
AU2003294930B2 (en) Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same
Klingemann The NK-92 cell line—30 years later: its impact on natural killer cell research and treatment of cancer
JP7062720B2 (ja) 細胞免疫療法のための方法および組成物
EP3641768B1 (en) Chimeric Antigen Receptors (CARs), Compositions and Associated Methods
Revoltella et al. Granulocyte–macrophage colony-stimulating factor as an autocrine survival-growth factor in human gliomas
Petersen et al. Improving T-cell expansion and function for adoptive T-cell therapy using ex vivo treatment with PI3Kδ inhibitors and VIP antagonists
Cooley et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu
Lozupone et al. Effect of human natural killer and γδ T cells on the growth of human autologous melanoma xenografts in SCID mice
EP4353750A2 (en) Chimeric antigen receptors (cars), compositions and methods thereof
US11945866B2 (en) Method of eliminating hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in a patient using bi-specific antibodies
CA3145510A1 (en) Nk cell composition and preparations for immunotherapy and methods for their production
TW201713768A (zh) 嵌合抗原受體（ｃａｒ）、組合物及其使用方法
CA2133075A1 (en) CD28 Pathway Immunoregulation
Gao et al. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells
CN112771080B (zh) 针对steap1的嵌合受体及其使用方法
KR20190003456A (ko) 면역치료의 항-종양 활성을 높이기 위한 중간엽 줄기세포
US20240245771A1 (en) Fully human antibody for human b7h3, chimeric antigen receptor and uses thereof
Yang et al. A novel activation pathway for mature thymocytes. Costimulation of CD2 (T, p50) and CD28 (T, p44) induces autocrine interleukin 2/interleukin 2 receptor-mediated cell proliferation.
Howells et al. Peripheral blood lymphocytes express the platelet‐type thrombin receptor
CA2404479A1 (en) Hybrid cytokine of il-7 and .beta.-chain of hepatocyte growth factor
KR20220119080A (ko) 치료용 종양-침윤 림프구들 배양을 위한 개선된 방법
Paganin et al. IL-4 inhibits binding and cytotoxicity of NK cells to vascular endothelium
AU2999299A (en) Methods and compositions for the selective expansion of gamma/delta t-cells
US20240207312A1 (en) Chimeric antigen receptor (car)-t cells
CN118284621A (zh) 抗flt3抗体、car、car t细胞和使用方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired